Hitachi is a pioneer in developing sophisticated scientific and medical systems and products. Hitachi fulfills the modern healthcare requirements by continually working toward development of new medical diagnostics products and biotechnology equipment. Hitachi also offers a comprehensive line of cutting-edge scientific equipment for a wide range of research applications.
Hitachi High Technologies America offers a wide breadth of product and service offerings which include semiconductor manufacturing equipment, analytical instrumentation, scientific instruments, and bio-related products.
Provides technologically advanced solutions to meet the diverse and complex challenges of materials science, biological research, and industrial manufacturing. Hitachi supports national laboratories, R&D facilities, and academia with a wide range of reliability-proven instrumentation, including scanning electron microscopy (SEM), analytical and biological transmission electron microscopy (TEM), dedicated STEM, focused ion beam (FIB), tabletop microscopes, atomic force microscopy (AFM), and microanalysis sample preparation systems.
Supports government researchers by fulfilling their need for scientific instrumentation via a wide range of reliability-proven offerings, including liquid chromatography, amino acid analyzers, UV-Vis/NIR and fluorescence spectroscopy systems, thermal analyzers, and X-ray fluorescence (XRF) solutions.
Hitachi has developed a reliable, stable and user-friendly charged particle therapy system (PROBEAT) which meets the growing needs of new and innovative solutions for cancer therapy. Charged particles can be delivered at very high speed, penetrating the body and releasing maximum energy to the targeted tumor. As a result, exposure of normal tissue to radiation is minimized, and higher radiation dose can be administered to the tumor area.
Hitachi has over 20 years of proven particle therapy technology experience and continues to define new technological limits by developing innovative analysis and fabrication techniques. In the future, Hitachi intends to continue to stay at the technology’s cutting edge of charged particle cancer therapy by enhancing the capabilities of the synchrotron accelerator for delivery of increasingly heavier particles such as carbon.